Search results
Results From The WOW.Com Content Network
A lower dose should be used in people with liver disease. [2] While it does not appear to be harmful during pregnancy, it has not been studied for this use. [3] It is unclear if it is safe for use during breastfeeding. [2] It is in the antihelmintic family of medications. [4] It works by paralyzing worms. [4] Pyrantel was initially described in ...
A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. [1] Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.
Individualized cancer immunotherapy, also referred to as individualized immuno-oncology, is a novel concept for therapeutic cancer vaccines that are truly personalized to a single individual. The human immune system is generally able to recognize and fight cancer cells .
To change this template's initial visibility, the |state= parameter may be used: {{Routes of administration, dosage forms | state = collapsed}} will show the template collapsed, i.e. hidden apart from its title bar. {{Routes of administration, dosage forms | state = expanded}} will show the template expanded, i.e. fully visible.
In the package insert of a German pyrantel drug ("Helmex"), it says dosage is 10mg/kg, with one tablet containing 720mg of pyrantel embonate equivalent to 250mg of pure pyrantel. I will mark the passage with citation needed. --Victor--H 09:28, 19 July 2011 (UTC) Per Reese's insert, dosage is 11mg/ml for pyrantel base.
CimaVax-EGF is a vaccine used to treat cancer, specifically non-small-cell lung carcinoma (NSCLC). CIMAvax-EGF is composed of recombinant human epidermal growth factor (EGF) conjugated to a protein carrier. [2] The vaccine was developed by the Center of Molecular Immunology, Havana, Cuba, and made available to the Cuban population in 2011.
A Vaccine Information Statement (VIS) is a document designed by the Centers for Disease Control and Prevention (CDC) to provide information to a patient receiving a vaccine in the United States. The National Childhood Vaccine Injury Act requires that medical professionals provide a VIS to patients before receiving certain vaccinations.
Personalized mRNA cancer vaccine therapy is a therapy that uses a personalized cancer vaccine based on mRNA vaccine technology to target existing tumors in patients. As of 2024, number of mRNA cancer vaccines are in clinical trials, of which many are personalized therapies based on engineering mRNA-mediated immune response that targets the patient's particular strain of cancer cells.